DELIVEREX

Serial Number 79282940
Registration 6405652
700

Registration Progress

Application Filed
Jan 31, 2020
Under Examination
Approved for Publication
Apr 20, 2021
Published for Opposition
Apr 20, 2021
Registered
Jul 6, 2021

Trademark Image

DELIVEREX

Basic Information

Serial Number
79282940
Registration Number
6405652
Filing Date
January 31, 2020
Registration Date
July 6, 2021
Published for Opposition
April 20, 2021
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Jul 6, 2021
Registration
Registered
Classes
005 044

Rights Holder

Evox Therapeutics Limited

24
Address
Oxford Science Park,
Medawar Centre, 2nd Floor East Building
GB

Ownership History

Evox Therapeutics Limited

Original Applicant
24
GB

Evox Therapeutics Limited

Owner at Publication
24
GB

Evox Therapeutics Limited

Original Registrant
24
GB

Legal Representation

Attorney
Bryce J. Maynard

USPTO Deadlines

Next Deadline
522 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20210706)
Due Date
July 06, 2027
Grace Period Ends
January 06, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

36 events
Date Code Type Description Documents
Dec 4, 2021 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Nov 23, 2021 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Nov 1, 2021 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Nov 1, 2021 FIMP P FINAL DISPOSITION PROCESSED Loading...
Oct 6, 2021 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Jul 6, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 4, 2021 LIME I LIMITATION FROM THE IB EXAMINED AND ENTERED Loading...
May 1, 2021 LIMG M LIMITATION OF GOODS RECEIVED FROM IB Loading...
Apr 20, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 20, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 18, 2021 GPNX P NOTIFICATION PROCESSED BY IB Loading...
Mar 31, 2021 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Mar 31, 2021 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Mar 31, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 13, 2021 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 13, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 13, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 13, 2021 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Mar 13, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 6, 2021 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Mar 6, 2021 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Mar 6, 2021 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jan 28, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 28, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 27, 2021 ALIE A ASSIGNED TO LIE Loading...
Oct 16, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 30, 2020 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
May 29, 2020 RFNT P REFUSAL PROCESSED BY IB Loading...
May 14, 2020 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
May 14, 2020 RFRR P REFUSAL PROCESSED BY MPU Loading...
Apr 30, 2020 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Apr 29, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 20, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 17, 2020 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Apr 13, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 9, 2020 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy
First Use Anywhere: 0
First Use in Commerce: 0
Class 044
Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Pseudo Mark
DELIVER EX

Classification

International Classes
005 044